ABSTRACT In Singapore, the approved influenza A (H1N1) vaccines are Panvax® and Pandemrix®. An estimated 425,000 doses of Panvax and less than 100 doses of Pandemrix had been distributed in Singapore from November 2009 to February 2010. Reviews on the H1N1 vaccine have concluded that it has a safety profile similar to that of seasonal influenza vaccines. From the time the H1N1 vaccination was implemented in Singapore on November 3, 2009, up to October 11, 2010, the Health Sciences Authority had received 173 adverse event reports from healthcare professionals. We report a case of prolonged illness after H1N1 vaccination.
INTRODUCTION
The first influenza pandemic in 41 years was declared by the vaccine. (2) Clinical trials that examined the immunogenicity, safety and tolerability of the H1N1 vaccine were conducted in healthy adults in Australia around July 2009. All adverse effects, including local (injection site) reactions and systemic symptoms (headache, myalgia and malaise), were reported to be of mild to moderate intensity and self-limiting. (3) We present a case of prolonged illness in a patient after receiving the H1N1 vaccine.
CASE REPORT
A 31-year-old Chinese woman with a history of appendisectomy was administered a H1N1 vaccine (Panvax  ® ; Physical examination revealed periorbital swelling, linear streaks of petechiae on the legs (Fig. 1) , purpura patches on the thigh (Fig. 2) , faint and non-palpable erythema on the arm and abdomen (Fig. 3) , and slightly injected tonsils. A diagnosis of exanthem caused by the H1N1 vaccine was made, and the patient was started on oral prednisolone and antihistamines, as well as topical betamethasone cream and emollients. The patient was also given gabapentin for her paresthesia. She had low-grade fever during her five-day stay in the hospital, and oral augmentin was administered for one week. At the time of her discharge, the body rash and arthralgia had improved.
At the subsequent outpatient follow-up, the patient continued to have recurrent pruritic rash; hence, prednisolone with a tapering-down dose was continued for almost four weeks. Investigation did not reveal any underlying autoimmune or connective tissue disease. The patient made a slow recovery with minimal symptoms until her review in September 2010. It is prepared in embryonated chicken eggs, employing the same standard techniques used for the production of seasonal trivalent inactivated vaccine.
Prolonged pruritic rash following influenza A (H1N1) vaccination
When assessing the safety of a vaccine, it is important to be aware of the background rates of diseases in the population, in order to separate legitimate safety concerns from events that are temporarily associated with, but not caused by, the vaccine. 
Notably, China reported an adverse event rate of 90 per million doses, (6) which is also slightly higher than that reported in the US. The second possible reason for the disparity could be the variance in the reporting system of different countries. As
Singapore has a highly efficient reporting system, the adverse event rate may be more accurately represented in Singapore than in other reporting systems, i.e. the VAERS and China CDC, reported as a generalised rash, of which 19 were pruritic rash. (4) Careful review of the Panvax product brochure revealed that generalised rash was not reported in healthy adults and children recruited in its clinical trials. Post-marketing surveillance revealed that pruritus, urticaria and rash were uncommon (i.e. ≥ 1/1,000 and < 1/100). (9) This is consistent with our local data.
The case that we have reported is likely to be an extremely rare reaction to the Panvax H1N1 vaccine. Further studies are required to standardise the treatment for this type of adverse reaction.
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Fig. 3 Photographs show faint and non-palpable er ythema on the patient's (a) arm and (b) abdomen.
